Sanofi X Paris 2024

At Sanofi, we’re proud to be premium partner of Paris 2024.

Our Latest Stories

Microscopic view of microglia – innate immune cells deep within the brain that promote inflammation and drive smoldering-associated worsening in MS

Your Health

September 13, 2024

Why Smoldering Neuroinflammation Must Be Part of the Discussion to Improve Care in Multiple Sclerosis

Shuang Yang, Scientist, China

Second quarter 2024 results

Second quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

Thursday July 25, 2024
14:30 - 16:00 CET (8:30am – 10am EST)

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Igniting the Potential in Everyone

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

5

Therapeutic areas

78

Compounds in clinical development

29

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases

September 12, 2024
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
September 11, 2024
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
September 11, 2024
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
September 10, 2024
Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône